Merck (NYSE: MRK) announced on Friday that four African countries had approved the use of the company's Ebola vaccine, Ervebo. The Democratic Republic of the Congo (DRC), Ghana, Zambia, and Burundi have all agreed to license the Ebola vaccine, with additional countries expected to approve the vaccine, as well, in the coming months.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,